This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
3 Medical Services Stocks to Buy Despite Near-Term Industry Woes
by Urmimala Biswas
The Zacks Medical - Services industry is growing on digital healthcare adoption. AMN, AMEH and LFMD are set to gain the most. However, falling healthcare spending may disrupt the trend.
Here's Why You Should Hold on to Illumina (ILMN) for Now
by Zacks Equity Research
Investors are optimistic about Illumina (ILMN) owing to its strength in international markets and notable strategic partnerships.
Abbott (ABT) Gets FDA Nod for New Cardiac Mapping System
by Zacks Equity Research
Abbott's (ABT) EnSite X EP System with EnSite Omnipolar Technology offers a 360-degree view of the heart, regardless of catheter orientation, for cardiac mapping without compromise.
Alcon (ALC) Launches Preservative-Free Drops for Dry Eye Relief
by Zacks Equity Research
Alcon's (ALC) new preservative-free solution for patients with dry eye symptoms is the latest addition to its leading global artificial tear brand Systane.
Masimo (MASI) Provides FY22 View, Preliminary FY21 Results Solid
by Zacks Equity Research
Masimo's (MASI) solid full-year results likely to have been boosted by strong product sales.
Bio Rad's (BIO) Product Launches Aid, Forex Woes Persist
by Zacks Equity Research
Bio Rad's (BIO) strength in its key product lines across major geographic regions buoys optimism.
Quest Diagnostics (DGX) Posts Preliminary Q4 & 2021 Results
by Zacks Equity Research
Quest Diagnostics (DGX) posts preliminary fourth-quarter and full-year results, reflecting an increase in COVID-19 testing services and a steady recovery in the company's base testing volumes.
Zacks.com featured highlights include: Accenture plc, Builders FirstSource, Inc. and AMN Healthcare Services, Inc.
by Zacks Equity Research
Accenture plc, Builders FirstSource, Inc. and AMN Healthcare Services, Inc. are included in this blog.
Integra (IART) Announces Preliminary Q4 & '21 Sales Results
by Zacks Equity Research
Integra's (IART) preliminary revenue results and recent plans to implement a $125-million share repurchase instill investor optimism.
Here's Why You Should Retain Thermo Fisher (TMO) Stock for Now
by Zacks Equity Research
Investors are optimistic about Thermo Fisher's (TMO) strong end-market growth and focus on international regions.
Here's Why You Should Retain Abiomed (ABMD) Stock For Now
by Zacks Equity Research
Investors remain optimistic about Abiomed (ABMD) due to its Impella product line's strength.
Inogen's (INGN) Preliminary Q4 Revenues Solid Amid Challenges
by Zacks Equity Research
Inogen's (INGN) revenue growth in the fourth quarter is likely to have been boosted by solid product sales despite supply chain constraints.
Cardiovascular Systems (CSII) Coronary Sales Up Amid COVID Woe
by Zacks Equity Research
Cardiovascular Systems (CSII) continues to experience strong demand for physician training and certification in all international markets.
Hologic (HOLX) Up on Preliminary Q1 Organic Sales Growth
by Zacks Equity Research
Hologic's (HOLX) Diagnostics division's preliminary numbers show a strong rebound in the base business.
Here's Why AMN Healthcare (AMN) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
AMN Healthcare (AMN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
3 Stocks With Momentum Anomaly to Create a Winning Portfolio
by Zacks Equity Research
Accenture (ACN), Builders FirstSource (BLDR) and AMN Healthcare Services (AMN) are currently witnessing a short-term pullback in price. So, make sure you take full advantage of it.
Here's Why You Should Hold on to Align Technology (ALGN) Now
by Zacks Equity Research
Investors are optimistic about Align Technology (ALGN) given huge market potential in its Invisalign brand and strategic partnerships.
Medtronic (MDT) Gets MHLW Approval for Micra AV Sale in Japan
by Zacks Equity Research
The Micra AV approval is likely to boost Medtronic's (MDT) Cardiac Rhythm Management business while delivering the benefits of leadless pacing in Japan.
Illumina (ILMN) Announces Preliminary Q4 Sales, Issues '22 View
by Zacks Equity Research
Illumina's (ILMN) preliminary fourth-quarter results, latest partnership deals and a robust pipeline of technologies instill investor optimism.
AMN Healthcare Services (AMN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
AMN Healthcare Services (AMN) closed the most recent trading day at $107.50, moving +0.41% from the previous trading session.
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to its slew of regulatory approvals and strategic buyouts.
Quidel Corporation (QDEL) Reports Solid Preliminary Q4 Revenues
by Zacks Equity Research
Quidel's (QDEL) revenue growth in the fourth quarter is likely to have been boosted by continued robust sales of its SARS-related products.
IDEXX's (IDXX) Low LPD Sales, Rise in Expenses Dampen Growth
by Zacks Equity Research
Distributor purchasing dynamics have an impact on IDEXX's (IDXX) reported sales of CAG products.
DexCom (DXCM) Posts Solid Preliminary Q4 and 2021 Revenues
by Zacks Equity Research
DexCom (DXCM) posts solid fourth-quarter and full-year 2021 revenue data on the back of resilience shown in the face of the COVID-19 induced challenges.
Here's Why You Should Retain AmerisourceBergen (ABC) Stock
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust pharmaceutical segment. However, stiff competition is a woe.